| P2093 | author name string | J McNatt | |
| | J T Willerson | |
| | L M Buja | |
| | P Golino | |
| | S K Yao | |
| | M Rosolowsky | |
| | F De Clerck | |
| P2860 | cites work | Isolation and Structure of Two Prostaglandin Endoperoxides That Cause Platelet Aggregation | Q28622645 |
| | Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial | Q34258431 |
| | Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells | Q34608006 |
| | Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets | Q35020372 |
| | Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis | Q35593380 |
| | Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs | Q35812008 |
| | Platelets interact with fibrin only after activation | Q36488574 |
| | Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells | Q37024612 |
| | Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications | Q38648794 |
| | The biochemical pharmacology of thromboxane synthase inhibition in man. | Q39834369 |
| | Thromboxane a2: biosynthesis and effects on platelets | Q40113741 |
| | Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. | Q40682170 |
| | Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin | Q41380863 |
| | Continued incorporation of circulating radiolabeled fibrinogen into preformed coronary artery thrombi | Q44373063 |
| | Urinary excretion of prostaglandin E2, prostaglandin F2 alpha, and thromboxane B2 in normotensive and hypertensive subjects on varying sodium intakes | Q46854085 |
| | Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis. | Q54112049 |
| | Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. | Q54127127 |
| | SQ 22536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor | Q58412227 |
| | Radioimmunoassay of Prostaglandins Fα, E1and E2in Human Plasma | Q67314548 |
| | Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation | Q68220963 |
| | R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro | Q69352638 |
| | Iliac artery mural thrombus formation. Effect of antiplatelet therapy on 111In-platelet deposition in baboons | Q69635954 |
| | Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator | Q69859494 |
| | Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction | Q69872060 |
| | Thromboxane synthase inhibition potentiates washed platelet activation by endogenous and exogenous arachidonic acid | Q69944964 |
| | Comparison of the interactions of fibrinogen and soluble fibrin with washed rabbit platelets stimulated with ADP | Q69957246 |
| | Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial | Q70275606 |
| | The influence of selective thromboxane synthetase inhibition with a novel imidazole derivative, UK-38,485, on prostanoid formation in man | Q70280909 |
| | The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial | Q70331348 |
| | Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation | Q70376888 |
| | Inhibition of platelet thromboxane synthesis by 7-(1-imidazolyl) heptanoic acid: dissociation from inhibition of aggregation | Q71592711 |
| | Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis | Q72909332 |
| | R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo | Q93514266 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombolysis | Q1931577 |
| | plasminogen | Q107129060 |
| P304 | page(s) | 1095-1102 | |
| P577 | publication date | 1990-10-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis | |
| P478 | volume | 86 | |